Clay Siegall is the Chief Executive Officer and the founder of Seattle Genetics. This is a biotech company that focuses majorly on the therapy drugs for the disorders that have not yet been improved over a decade. Clay went to the University of Maryland and earned BS in zoology and later joined George Washington University and received Ph.D. in genetics. He founded the Seattle Genetic in 1998 and has been able to provide the best leadership to this firm making it to be leading in the targeted therapy industry. It is his firm that was the first one to develop the FDA-approved antibody drug and besides it has been able to have a strong partnership with drug manufacturers such as Bayer, Pfizer, and Genentech amongst many more.
In the cancer research industry, Clay Siegall is prominent due to his significant contribution, and it is his aim to ensure all the future goals of this firm are accomplished. A lot of drugs have been invested, and they are replacing the old methods of treating cancer. The drugs that have been developed are proven to be of great quality and efficacy thus they will react well to the patient. The idea that Clay Siegall had in genetics started long ago because he had an interest in medicine field and the need to overcome the diseases. His first interest was on cancer treatment, and by then he was pursuing his degree in zoology where one of the family members was severely sick with cancer, but the chemotherapy made that person to almost die. It is from there that the passion grew and became intense and he decided to venture into the field of genetics so that he can explore and discover more.
Seattle Genetics gets its money through the selling of their branded drugs since it is a company that is competitive when it comes to drugs that are approved by FDA. Also, it earns some cash from licensing their technology that they own when other partners intend to use it. The success of Clay Siegall has been achieved through hard work and dedication to his job as that has been his driving factor.